Inpharma Weekly

, Volume 1407, Issue 1, pp 18–18 | Cite as

Alemtuzumab promising for advanced or refractory lymphoproliferative disorders

Clinical study
  • 4 Downloads

Keywords

Related Event Conventional Treatment Infectious Complication Haematological Toxicity Alemtuzumab 

Copyright information

© Adis International Ltd 2003

Personalised recommendations